Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/27/2025 | $3.50 | Overweight | Barclays |
| 5/14/2025 | $4.00 | Buy | H.C. Wainwright |
| 12/20/2024 | $12.00 → $15.00 | Buy | H.C. Wainwright |
| 12/11/2023 | $6.00 | Buy | H.C. Wainwright |
| 8/14/2023 | $2.75 → $3.50 | Underweight → Neutral | Piper Sandler |
| 6/22/2023 | $6.00 | Overweight | Cantor Fitzgerald |
| 5/16/2022 | $10.00 → $4.00 | Overweight → Underweight | Piper Sandler |
| 10/29/2021 | $17.00 | Outperform | Cowen & Co. |
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
Barclays initiated coverage of Humacyte with a rating of Overweight and set a new price target of $3.50
H.C. Wainwright resumed coverage of Humacyte with a rating of Buy and set a new price target of $4.00
H.C. Wainwright reiterated coverage of Humacyte with a rating of Buy and set a new price target of $15.00 from $12.00 previously
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
8-K - Humacyte, Inc. (0001818382) (Filer)
424B3 - Humacyte, Inc. (0001818382) (Filer)
DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60.0 million worth of its common stock and warrants in an oversubscribed registered direct offering. Under the terms of the securities purchase agreement, the Company has agreed to sell 28,436,018 shares of its common stock and warrants to purchase 28,436,018 shares of common stock. The warrants will become exercisable 180 days following
- Results published in Oxford Academic's Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication in Oxford Academic's Military Medicine of positive long-term results from its humanitarian program using Symvess to treat wartime vascular trauma injuries in Ukraine. The publication, titled "Evaluating the Safety and Efficacy of Humacyte Acellu
– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus – DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the allowance of a U.S. Patent covering the composition of a bioengineered esophagus that can be produced using the Company's proprietary regenerative tissue engineering platform. The patent, titled "Tubular
BioAesthetics Corporation announced today the appointment of Juliana Blum, PhD as its new Chief Executive Officer, effective August 12, 2024. Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO of Toragen, Inc. said, "This is an important milestone for BioAesthetics. During the development of every successful biotech company, there comes a time when the founding CEO transitions to a different role and a new CEO with different skill sets is needed for product advancement and commercialization. Dr. Blum's experience with novel products as co-founder of Humacyte will help guide further progress at BioAesthetics." Dr. Blum joins BioAesthetics following her 20 years spent as Co-founder
DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors. "Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board," said Kathleen Sebelius, Chair of Humacyte's board of directors. "Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV). We al
--Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle-- --Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications-- DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Shamik J. Parikh, M.D., as Chief Medical Officer. In this role, Dr. Parikh will lead the company's global clinical development strategy, including oversight of the preclinical and clinical
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, August 11, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Second Quarter 2025 Financial Results and Corporate UpdateDate:August 11, 2025Time:8:00 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13754596 (Conference ID)Call meTM Feature: Click Here
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to provide a corporate and financial update. Title:Humacyte First Quarter 2025 Financial Results and Corporate UpdateDate:May 13, 2025Time:8:30 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13753487 (Conference ID)Call meTM Feature: Click HereWebc
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025. Management will host a webcast and conference call at 8:30 a.m. ET. Title:Humacyte Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdateDate:March 28, 2025Time:8:30 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13751524 (Conference ID)Call meTM Feature: Click HereWebcast:C